ライフサイエンスコーパス: attenuated vaccine

1 eltawzy, was created and evaluated as a live attenuated vaccine.

2 lly serve as a positive-marker modified live-attenuated vaccine.

3 ed vaccine as compared with those given live attenuated vaccine.

4 ed for the inactivated vaccines and the live attenuated vaccine.

5 ccine and 36% (95% CI, 0 to 59) for the live attenuated vaccine.

6 that the M2KO virus has potential as a live attenuated vaccine.

7 ants (median age, 11 weeks) administered the attenuated vaccine.

8 hat can be used in the development of a live attenuated vaccine.

9 9% (95% CI, -113 to 33; P=0.55) for the live attenuated vaccine.

10 at it may serve as the starting point for an attenuated vaccine.

11 formation to take steps toward developing an attenuated vaccine.

12 a safe and potentially more efficacious live attenuated vaccine.

13 pism of a virus is a new approach for a live attenuated vaccine.

14 r protection and support advancement of this attenuated vaccine.

15 hich combines the advantages of DNA and live attenuated vaccines.

16 t can be mutated to generate successful live attenuated vaccines.

17 culture has hindered the development of live-attenuated vaccines.

18 ines but not in children who received highly attenuated vaccines.

19 ontribute to virulence, and could be used as attenuated vaccines.

20 serve as a model for the rational design of attenuated vaccines.

21 tic deletion to produce whole parasite-based attenuated vaccines.

22 that induced by live virus and possibly live attenuated vaccines.

23 ors, and may differ for inactivated and live attenuated vaccines.

24 with vhs deleted have been proposed as live-attenuated vaccines.

25 r approach for prevention is the use of live attenuated vaccines.

26 erstand virus biology and develop novel live attenuated vaccines.

27 inactivated vaccines and cold-adapted, live attenuated vaccines.

28 or development of classical swine fever live attenuated vaccines.

29 e pathogenesis of HAV and the development of attenuated vaccines.

30 poor or diminished efficacy compared to live attenuated vaccines.

31 d activity is a strategy for generating live-attenuated vaccines.

32 e identities (>/=98%) with the modified live-attenuated vaccines.

33 acteristics desirable in candidates for live attenuated vaccines.

34 imals (DIVA tests) for established killed or attenuated vaccines.

35 ay be more informative on the safety of live-attenuated vaccines.

36 on as safe, immunogenic, and protective live-attenuated vaccines.

37 o and supports targeting the SH gene in live attenuated vaccines.

38 s are good candidates for the design of live attenuated vaccines.

39 ILTV vaccines are less efficacious than live attenuated vaccines.

40 y attenuate hMPV for the development of live attenuated vaccines.

41 aramyxoviruses for rationally designing live attenuated vaccines.

42 r receipt of dose 1 among recipients of live attenuated vaccine (3.8%) than among recipients of inact

43 We propose that this live attenuated vaccine acts like a silent natural infection

44 Immunization with live, attenuated vaccine (administered intranasally) is not cu

45 We studied respiratory delivery of an attenuated vaccine against Blastomyces dermatitidis.

46 tential strategy to develop a neurovirulence-attenuated vaccine against chickenpox and herpes zoster

47 , this is the first example of a recombinant attenuated vaccine against fungi.

48 implications for developing a modified live-attenuated vaccine against HEV.

49 d to develop a two-component, trivalent live attenuated vaccine against human parainfluenza virus typ

50 ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis, using

51 most promising candidates for a genetically attenuated vaccine against malaria (5) , as a unique and

52 s DNA clone as a genetically engineered live-attenuated vaccine against PCV2 infection and PMWS.

53 ned F. novicida mutant (DeltaiglC) as a live attenuated vaccine against subsequent intranasal challen

54 ted mainly to reduced protection of the live attenuated vaccine against type B viruses.

55 e possibilities for developing improved live attenuated vaccines against arteriviruses and other viru

56 ons for development of both subunit and live-attenuated vaccines against ETEC and other enteric patho

57 eficient chlamydial strains function as live attenuated vaccines against genital and ocular infection

58 oplasmic tail mutants have potential as live attenuated vaccines against H5N1 influenza viruses.

59 feasibility of using M2 tail mutants as live attenuated vaccines against H5N1 virus.

60 s show significant promise as potential live-attenuated vaccines against human immunodeficiency virus

61 imilar approach may guide the design of live-attenuated vaccines against Lassa and other arenaviral h

62 the polymerase could be used to design live attenuated vaccines against serious pathogens within the

63 t provides a new approach to generating live attenuated vaccines against this class of virus.

64 erapeutics and the development of killed and attenuated vaccines against this important emerging path

65 At least 14 different live attenuated vaccines against this pathogen are available

66 ) and Card9(-/-) mice immunized with a live, attenuated vaccine also fail to acquire protective immun

67 The live attenuated vaccine also prevented influenza illnesses bu

68 The live attenuated vaccine also prevented influenza illnesses bu

69 However, live attenuated vaccines also induce strong CD8 T cell respon

70 Among live attenuated vaccine and placebo recipients, cases were le

71 lity control of new lots of the current live-attenuated vaccine and provide insight for the rational

72 ebo-controlled trial of inactivated and live attenuated vaccines and compared titers in subjects with

73 s display characteristics desirable for live attenuated vaccines and hold potential as vaccine candid

74 r mucosal application in humans, use of live-attenuated vaccines and microbial vectors, and productio

75 diate this process will aid in the design of attenuated vaccines and of novel therapeutics.

76 uperseded by a final report, studies of live-attenuated vaccine, and studies of prepandemic seasonal

77 responses similar to those elicited by live-attenuated vaccines, and its flexibility permits the fas

78 ebo-controlled trial of inactivated and live attenuated vaccines, and we evaluated the laboratory end

79 Live attenuated vaccines appear to be the most effective in c

80 ine appeared to be efficacious, whereas live attenuated vaccine appeared to be less so.

81 However, the live-attenuated vaccine approach faces formidable obstacles,

82 Although live, attenuated vaccines are available to protect several ani

83 Novel live attenuated vaccines are being developed that promise gre

84 Live attenuated vaccines are commonly used in the poultry ind

85 Live attenuated vaccines are considered the most viable vacci

86 nd the potential to develop multivalent live-attenuated vaccines are discussed.

87 Live attenuated vaccines are more immunogenic and have the ca

88 ge to lentiviral vaccine immunity, even when attenuated vaccines are used that, to date, achieve the

89 ay serve as a novel approach to develop live attenuated vaccines as well as antiviral drugs for pneum

90 The superior efficacy of live attenuated vaccine, as compared with inactivated vaccine

91 y can lead to the development of novel, live attenuated vaccines, as well as antiviral drugs for pneu

92 irway selectively recruited airway Tregs and attenuated vaccine-augmented disease, reducing weight lo

93 D vaccine is one of the most successful live attenuated vaccines available.

94 rulence factors, we hypothesized that a live-attenuated vaccine based on PA14 might elicit a broader

95 nstrated the feasibility of creating defined attenuated vaccines based on a type A strain.

96 deration should be taken when designing live attenuated vaccines based on deletions of nonstructural

97 venue for the development of arenavirus live attenuated vaccines based on rearrangement of their vira

98 ed drastically following the introduction of attenuated vaccines, but progress toward the eradication

99 A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route ma

100 The fact that uncontrolled replication of an attenuated vaccine can lead to regaining of its virulenc

101 Although live attenuated vaccines can provide potent protection agains

102 f the p27 gene could be considered as a live attenuated vaccine candidate against visceral leishmania

103 Thus, ML29 is a promising attenuated vaccine candidate for Lassa fever.

104 hat the immunogenicity in primates of a live-attenuated vaccine candidate for parainfluenza virus typ

105 is not available, and the more advanced live attenuated vaccine candidate in clinical trials requires

106 was then assessed for its efficacy as a live attenuated vaccine candidate in mice after challenge wit

107 Currently, the most promising live-attenuated vaccine candidate is a temperature-sensitive

108 The attenuated vaccine candidate is expected to be safe and

109 n RacL11 in comparison to infection with the attenuated vaccine candidate strain KyA.

110 Here we report on a live-attenuated vaccine candidate that contains a 10-nucleoti

111 ike HEp-2 cells, in which wild-type and live-attenuated vaccine candidate viruses grow equally well,

112 elA DeltaspoT mutant may be a promising live-attenuated vaccine candidate.

113 suggesting its potential as the basis of an attenuated vaccine candidate.

114 y of a CD-based approach for developing live-attenuated vaccine candidates against human-pathogenic a

115 viruses might have a great potential as live attenuated vaccine candidates against SIV infections of

116 ene rearrangement as a means to develop live attenuated vaccine candidates against Vesicular stomatit

117 onal development of safe and protective live attenuated vaccine candidates based on genome reorganiza

118 We therefore generated 2 live-attenuated vaccine candidates based on the insertion of

119 f the virus, many of which were developed as attenuated vaccine candidates by serial passage in fibro

120 t also will lead to the development new live attenuated vaccine candidates for hMPV.

121 be assembled and have been developed as live attenuated vaccine candidates for several flaviviruses.

122 ential for further development as novel live attenuated vaccine candidates that may rapidly control d

123 fely attenuate FMDV and further develop live attenuated vaccine candidates to control such a feared l

124 genicity, justifying their inclusion in live attenuated vaccine candidates to protect against the cur

125 testing the potential of the three forms as attenuated vaccine candidates, strain 4295 was inoculate

126 s but suboptimal substitutions provides live attenuated vaccine candidates.

127 ype recombinant RSV, supporting their use as attenuated vaccine candidates.

128 issues, and identification of potential live-attenuated vaccine candidates.

129 d form the basis of a new generation of live attenuated vaccine candidates.

130 The current live attenuated vaccines (chicken embryo origin [CEO] and tis

131 The reference attenuated vaccine combined with these variant Env chall

132 nogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant severe ac

133 xed viral populations and indicate that live-attenuated vaccines containing virulent virus may be saf

134 needed of the host response to HRSV and its attenuated vaccine derivatives.

135 -Japanese encephalitis (JE), the first live- attenuated vaccine developed with this technology has su

136 s lower respiratory tract and bear upon live attenuated vaccine development.

137 o the development of safe and effective live attenuated vaccines directed against VEEV and other rela

138 o the development of safe and effective live attenuated vaccines directed against VEEV and perhaps ot

139 e of virulent revertant viruses in some live-attenuated vaccines, disease from vaccination is rare.

140 hus far, the goal of developing a safe, live attenuated vaccine effective after a single dose has rem

141 Thus, multivalent live-attenuated vaccines elicit multifactorial protective imm

142 Isolation frequency was lowest among live attenuated vaccine failures, a reflection of lower speci

143 immune response and may have value as a live attenuated vaccine for aquaculture.

144 We developed an experimental live-attenuated vaccine for direct inoculation of the respira

145 reviously reported that an experimental live attenuated vaccine for equine infectious anemia virus (E

146 Development of a live attenuated vaccine for human NoV has not been possible b

147 Development of an attenuated vaccine for HuNoV has been hampered by the in

148 A live-attenuated vaccine for RVF, the MP-12 vaccine, is condit

149 d an opportunity to design a successful live-attenuated vaccine for SARS-CoV and opens avenues for tr

150 herefore, NU14 DeltawaaL is a candidate live-attenuated vaccine for the treatment and prevention of a

151 The absolute efficacies of the live attenuated vaccine for these end points were 8% (95% CI,

152 a decade is required for approval of a live, attenuated vaccine for use in humans.

153 approach for the rational design of stable, attenuated vaccines for a wide variety of viruses.

154 as a novel target to rationally design live attenuated vaccines for aMPV and perhaps other paramyxov

155 ding may also enable the development of live attenuated vaccines for both RSV and other members of th

156 The utility of live attenuated vaccines for controlling HIV epidemics is bei

157 approach to produce safe and effective live-attenuated vaccines for DENV and other insect-borne viru

158 Two live-attenuated vaccines for gastroenteritis (Rotateq [Merck]

159 the development of safe and efficacious live attenuated vaccines for hMPV and other human paramyxovir

160 as a novel target to rationally design live attenuated vaccines for hMPV and perhaps other paramyxov

161 n rates may become a new strategy to develop attenuated vaccines for humans and animals.

162 ster donor strain for the generation of live attenuated vaccines for humans and livestock.

163 would add an HPV component to existing live attenuated vaccines for measles and typhoid fever.

164 The design of attenuated vaccines for respiratory syncytial virus (RSV

165 also facilitate the development of new live attenuated vaccines for VSV, and perhaps other NNS RNA v

166 Among young children, live attenuated vaccine had significantly better efficacy tha

167 Development of live, attenuated vaccines has traditionally relied on empirica

168 Although live-attenuated vaccines have been safely administered to RSV

169 Live, attenuated vaccines have prevented morbidity and mortali

170 ed in various animal lentivirus models, live attenuated vaccines have proven to be the most effective

171 However, the existing live-attenuated vaccines have the potential to revert to viru

172 RSV DeltaSH has been tested as a live attenuated vaccine in humans and cattle, and here we dem

173 s and has the potential to be used as a live-attenuated vaccine in humans.

174 ent Chlamydia trachomatis to serve as a live attenuated vaccine in the genital tract.

175 e serious adverse events than any other live attenuated vaccine in use today.

176 Because concerns exist about the use of live-attenuated vaccines in immunocompromised individuals, a

177 protective immune mechanisms induced by live attenuated vaccines in primate models will be useful for

178 All eight live attenuated vaccines, including Japanese encephalitis vir

179 ed to further define the nature of the live, attenuated vaccine-induced immunity against Coccidioides

180 Two attenuated vaccines, Ingelvac PRRS MLV and Ingelvac PRRS

181 ogy, including human host-pathogen and live, attenuated vaccine interactions; host and cell type rest

182 ancestral immunogens, because the Env of the attenuated vaccine is a direct ancestor to the variant p

183 e vaccine than the previously developed live attenuated vaccine is needed for combating Francisella t

184 ptive immune response generated to this live attenuated vaccine is regulated by both the presence of

185 A live attenuated vaccine is the most promising vaccine strateg

186 reassortant (ML29) is a LASV candidate live-attenuated vaccine (LAV) that has shown promising result

187 dmonston-Zagreb has long been used as a live-attenuated vaccine (LAV) to protect against measles, not

188 Implementation of live-attenuated vaccines (LAV) will represent a major step in

189 Live-attenuated vaccines (LAVs) are the most advanced vaccine

190 RSV live-attenuated vaccines (LAVs) have a history of safe testin

191 Vaccination with live attenuated vaccines (LAVs) is an effective way for preve

192 Implementation of live-attenuated vaccines (LAVs) will represent a major step t

193 enge in a goat model as compared to the live attenuated vaccine MAP316F.

194 Attenuated vaccines may therefore lack sufficient innate

195 Successful live attenuated vaccines mimic natural exposure to pathogens

196 In an attenuated vaccine model, approximately 60% of animals i

197 Boosting T cell-mediated immunity by live attenuated vaccine Mycobacterium bovis bacillus Calmette

198 cted in mice immunized with the current live attenuated vaccine, Mycobacterium bovis-bacillus Calmett

199 nd safety concerns regarding the use of live attenuated vaccines or potent adjuvants in this populati

200 The multivalent live-attenuated vaccines overcame prior problems involving im

201 pening the possibility for its use as a live-attenuated vaccine platform for ZIKV and other clinicall

202 report the development of a recombinant live-attenuated vaccine platform strain that retains the pote

203 As modified mRNA and live-attenuated vaccine platforms can restrict in utero trans

204 l NS1 protein have emerged as promising live attenuated vaccine platforms.

205 ovel technology to sufficiently deliver live attenuated vaccine powders into the skin.

206 Live-attenuated vaccines present safety challenges, and prote

207 valent rotavirus vaccine (RV5), a live, oral attenuated vaccine, prevented 98% of severe rotavirus di

208 Both attenuated vaccines produced an approximately tenfold lo

209 Although a live-attenuated vaccine protects against MV, vaccination effi

210 nza A (H3N2), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inactivate

211 ymphocytes after immune activation with live attenuated vaccines remain poorly characterized.

212 ected: 18 and 12 peptides for the killed and attenuated vaccines, respectively.

213 f the risks and benefits indicates that live attenuated vaccine should be a highly effective, safe va

214 Finally, using the mutant as a live-attenuated vaccine showed significant promise for possib

215 s of JUNV have been documented, and a highly attenuated vaccine strain (Candid #1) was generated and

216 cDNA clones of segments A and B between the attenuated vaccine strain (D78) and the virulent IM or G

217 igen polymerase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.LVS::D

218 Whereas an F. tularensis live, attenuated vaccine strain (LVS) is the basis of an inves

219 llei Deltaasd mutant may be a promising live attenuated vaccine strain and a biosafe strain for consi

220 us in a dimorphic fungus, we have created an attenuated vaccine strain and have begun to elucidate fu

221 some success in animal models, including an attenuated vaccine strain based on an isolate from La Re

222 otection against plague, we developed a live-attenuated vaccine strain by deleting the Braun lipoprot

223 on, DeltaP(rfaH178), was introduced into the attenuated vaccine strain chi9241 (DeltapabA DeltapabB D

224 the highly pathogenic Brescia strain and the attenuated vaccine strain CS were constructed and evalua

225 In the context of an attenuated vaccine strain delivering the pneumococcal an

226 ptomic analysis of the M. gallisepticum live attenuated vaccine strain F and the virulent strain R(lo

227 A desirable trait in an effective live attenuated vaccine strain is an ability to persist withi

228 Two strains were evaluated: the attenuated vaccine strain LaSota (NDV-LS) that replicate

229 Importantly, both the attenuated vaccine strain MP12 and the fully virulent st

230 virulent Mycobacterium tuberculosis with the attenuated vaccine strain Mycobacterium bovis bacillus C

231 rensis organisms were comparable to the live attenuated vaccine strain of Francisella tularensis subs

232 Candid#1 (Cd1) is an attenuated vaccine strain of Junin virus, the causative

233 ity of the glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replication an

234 c-resistance markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotyp

235 ction of human intestinal xenografts with an attenuated vaccine strain of shigella (CVD1203) induced

236 A candidate live attenuated vaccine strain was constructed for West Nile

237 SC602 (icsA iuc), a well-characterized live attenuated vaccine strain which has undergone several cl

238 We used the live attenuated vaccine strain YFV-17D, which contains many m

239 (cryo-EM), we determined the structure of an attenuated vaccine strain, TC-83, of VEEV to 4.4 A resol

240 transformant could serve as a nonrevertible, attenuated vaccine strain.

241 nd livers than SL3261, the aroA mutant, live attenuated vaccine strain.

242 entity to explain her susceptibility to this attenuated vaccine strain.

243 reverse genetics, a set of experimental live attenuated vaccine strains based on recombinant H5N1 inf

244 Prototype attenuated vaccine strains CVD 1921 and CVD 1941, derive

245 Obtaining stably attenuated vaccine strains has traditionally been an emp

246 We have previously shown that attenuated vaccine strains of measles virus have potent

247 acterize a sample of 43 field isolates and 4 attenuated vaccine strains of Pasteurella multocida reco

248 ghout the poliovirus genome yielded the live attenuated vaccine strains of poliovirus.

249 Live attenuated vaccine strains of pseudorabies virus (PRV),

250 xpression systems and designing new types of attenuated vaccine strains of VEEV and EEEV.

251 strains of Salmonella may be useful as live attenuated vaccine strains or as vehicles for heterologo

252 uld be harnessed for the development of live-attenuated vaccine strains to combat HFAs.

253 Live attenuated vaccine strains, such as type I nonreplicatin

254 host and warrant further development as live-attenuated vaccine strains.

255 nd a strong proinflammatory reaction to live attenuated vaccine strains.

256 ght be used to reduce reactogenicity of live attenuated vaccine strains.

257 engineered polymerases might serve as live, attenuated vaccine strains.

258 Live attenuated vaccines such as SIV with a deleted nef gene

259 DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived pepti

260 ed influenza in the group that received live attenuated vaccine than in the group that received inact

261 stration of dose 1 was more common with live attenuated vaccine than with inactivated vaccine, primar

262 We describe a live-attenuated vaccine that is safe and efficacious in preve

263 ribe the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C57BL/6

264 Thus, it might be possible to develop live-attenuated vaccines that are as immunogenic as parental

265 has resulted in the development of two live, attenuated vaccines that are now licensed in many countr

266 radic epidemics remain unconfirmed, although attenuated vaccines that retain a low level of virulence

267 might be deleted for the development of live attenuated vaccines that would be safer to use in situat

268 As a safe alternative to live attenuated vaccines, the immunogenicity and protective e

269 Similar to a live attenuated vaccine, this approach should allow immunolog

270 didates demonstrate the potential for a live attenuated vaccine to protect against disease caused by

271 venging host iron and have been used in live-attenuated vaccines to combat plague epidemics.

272 Yersinia species have been utilized as live attenuated vaccines to prime protective immunity against

273 Live-attenuated vaccines typically offer rapid and durable im

274 nant Sendai virus (rSeV) was used as a live, attenuated vaccine vector for intranasal inoculation and

275 expression of heterologous antigens by live, attenuated vaccine vector strains of Vibrio cholerae is

276 Live attenuated vaccine vectors based on recombinant vesicula

277 dings show that the immunogenicity of a live-attenuated vaccine virus in primates can be enhanced wit

278 Vaccination of mice with a live attenuated vaccine virus induces potent protection again

279 othesized that persistent replication of the attenuated vaccine virus modulates inflammatory response

280 Immunization with a live attenuated vaccine virus prior to challenge protected al

281 increase the level of attenuation of a live-attenuated vaccine virus.

282 Attenuated vaccine viruses can be used to investigate th

283 tive of restricted viral replication of live attenuated vaccine viruses in humans.

284 ains unclear whether the replication of live attenuated vaccine viruses will be similarly enhanced wh

285 ding three pathogenic field isolates and two attenuated vaccine viruses.

286 tenuation and host-range restriction of live attenuated vaccine viruses.

287 However, the live attenuated vaccine was found to be ineffective among chi

288 ve (95% CI, 47 to 70; P<0.001), and the live attenuated vaccine was not observed to be effective (vac

289 stalk and catalytic domains of NA as a live attenuated vaccine was shown to confer a strong IAV-spec

290 The efficacy of the live attenuated vaccine was slightly less than that of the in

291 16-2017 A(H1N1)pdm09 strain used in the live attenuated vaccine was unchanged from 2015-2016, the Adv

292 The live-attenuated vaccine was used to assess the impact of the

293 The absolute efficacies of the live attenuated vaccine were 57% (95% CI, -3 to 82), 48% (95%

294 and human infections, new candidate H5 live attenuated vaccines were developed by using two differen

295 ion were higher among the recipients of live attenuated vaccine who were 6 to 11 months of age (6.1%)

296 nd control are under development, and a live attenuated vaccine with substantial potential for contro

297 fer a general approach to the development of attenuated vaccines with well-defined antigenicities and

298 ine and 29% (95% CI, -14 to 55) for the live attenuated vaccine, with a relative efficacy of 60% (95%

299 A single intranasal administration of live attenuated vaccine without adjuvant was sufficient to in

300 An effective live attenuated vaccine would be extremely useful in the prev